Key Drivers
- Strong liquidity
- No revenue
- Negative cash flow
AIAI Summary
MAZE is now best viewed as a well-funded, multi-catalyst clinical-stage biotech with dilution risk largely removed through 2029, but the investment hinges on whether MZE829 and MZE782 can deliver clean proof-of-concept and break above the 29.0–29.3 resistance zone, since any weak data or enrollment delay could quickly reset the valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •No revenue
- •Negative cash flow
MAZE has an exceptionally strong liquidity position and low leverage, but persistent losses, negative cash flow, and no revenue keep the investment case fundamentally weak despite an elevated valuation.
Price Behavior
Key Price Behavior Insights:
- •Base holding
- •Lower highs
- •Resistance cap
Over the last month, MAZE has been consolidating with mildly weak momentum, holding the $26.92–$27.70 support zone but still capped by $29.0–$29.3 resistance.
Lower highs and a quick drop back to $27.18 after the
Sentiment & News
Key News Insights:
- •Pipeline momentum
- •Strong cash runway
- •Board expansion
Maze Therapeutics reported encouraging Q2 progress across MZE829 and MZE782, backed by a strong $495 million cash position and a long runway into 2029, supporting a constructive near-term outlook.
The update is modestly positive for MAZE, as advancing clinical programs and ample funding improve execution visibility and support the stock's upside narrative
Similar Companies in Healthcare
Other companies in the same sector with AI ratings